PL378748A1 - Zastosowanie selektywnych agonistów receptora EP2 w leczeniu - Google Patents

Zastosowanie selektywnych agonistów receptora EP2 w leczeniu

Info

Publication number
PL378748A1
PL378748A1 PL378748A PL37874804A PL378748A1 PL 378748 A1 PL378748 A1 PL 378748A1 PL 378748 A PL378748 A PL 378748A PL 37874804 A PL37874804 A PL 37874804A PL 378748 A1 PL378748 A1 PL 378748A1
Authority
PL
Poland
Prior art keywords
medical treatment
receptor agonists
selective receptor
selective
agonists
Prior art date
Application number
PL378748A
Other languages
English (en)
Polish (pl)
Inventor
Alexander Angelo Constan
Prakash Raj Keshary
David Burton Maclean
Vishwas Madhav Paralkar
Doina Cosma Roman
David Duane Thompson
Timothy Michael Wright
Original Assignee
Pfizer Products Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer Products Inc. filed Critical Pfizer Products Inc.
Publication of PL378748A1 publication Critical patent/PL378748A1/pl

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/433—Thidiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/02—Non-specific cardiovascular stimulants, e.g. drugs for syncope, antihypotensives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pulmonology (AREA)
  • Immunology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Rheumatology (AREA)
  • Dermatology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Heterocyclic Compounds Containing Sulfur Atoms (AREA)
  • Pyridine Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
PL378748A 2003-03-04 2004-02-23 Zastosowanie selektywnych agonistów receptora EP2 w leczeniu PL378748A1 (pl)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US45188903P 2003-03-04 2003-03-04

Publications (1)

Publication Number Publication Date
PL378748A1 true PL378748A1 (pl) 2006-05-15

Family

ID=32962656

Family Applications (1)

Application Number Title Priority Date Filing Date
PL378748A PL378748A1 (pl) 2003-03-04 2004-02-23 Zastosowanie selektywnych agonistów receptora EP2 w leczeniu

Country Status (14)

Country Link
EP (1) EP1601351A1 (pt)
JP (1) JP2006519250A (pt)
KR (1) KR20050105511A (pt)
CN (1) CN1859903A (pt)
AU (1) AU2004216898A1 (pt)
BR (1) BRPI0408061A (pt)
CA (1) CA2518193A1 (pt)
CL (1) CL2004000412A1 (pt)
MX (1) MXPA05009398A (pt)
NZ (1) NZ541828A (pt)
PL (1) PL378748A1 (pt)
TW (1) TW200424176A (pt)
WO (1) WO2004078169A1 (pt)
ZA (1) ZA200506532B (pt)

Families Citing this family (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0302094D0 (en) 2003-01-29 2003-02-26 Pharmagene Lab Ltd EP4 receptor antagonists
WO2005009468A1 (ja) * 2003-07-25 2005-02-03 Ono Pharmaceutical Co., Ltd. 軟骨関連疾患治療剤
GB0324269D0 (en) 2003-10-16 2003-11-19 Pharmagene Lab Ltd EP4 receptor antagonists
US8604055B2 (en) 2004-12-31 2013-12-10 Dr. Reddy's Laboratories Ltd. Substituted benzylamino quinolines as cholesterol ester-transfer protein inhibitors
MX2007007919A (es) 2004-12-31 2008-01-22 Reddy Us Therapeutics Inc Nuevos derivados de bencilaminas como inhibidores de la proteina de transferencia de colesteril-ester(cetp).
US7915316B2 (en) 2005-08-22 2011-03-29 Allergan, Inc Sulfonamides
US7696235B2 (en) * 2005-08-29 2010-04-13 Allergan, Inc. EP2 receptor agonists for treating glaucoma
EP1999255A2 (en) 2006-03-24 2008-12-10 The Children's Medical Center Corporation Method to modulate hematopoietic stem cell growth
AU2007280130B2 (en) 2006-07-28 2011-09-22 Pfizer Products Inc. EP2 agonists
EP3824885A1 (en) * 2006-10-20 2021-05-26 Children's Medical Center Corporation Method to enhance tissue regeneration
HUE025137T2 (en) * 2007-08-21 2016-01-28 Senomyx Inc Compositions are bitter taste blocking (blocking) compounds
HRP20190509T1 (hr) * 2008-03-12 2019-05-03 Ube Industries, Ltd. Spoj piridilaminooctene kiseline
WO2010091052A2 (en) 2009-02-03 2010-08-12 Children's Medical Center Corporation Methods for enhancing hematopoietic stem/progenitor cell engraftment
WO2010096264A2 (en) 2009-02-03 2010-08-26 Children's Medical Center Corporation Methods for enhancing hematopoietic stem/progenitor cell engraftment
PT2415763E (pt) 2009-03-30 2016-03-30 Ube Industries Composição farmacêutica para tratamento ou prevenção do glaucoma
WO2010116270A1 (en) 2009-04-10 2010-10-14 Pfizer Inc. Ep2/4 agonists
CN102498101A (zh) * 2009-09-11 2012-06-13 宇部兴产株式会社 苯胺化合物
JP2011057633A (ja) * 2009-09-11 2011-03-24 Ube Industries Ltd ピリジルアミノ酢酸化合物を含有する医薬
WO2011030871A1 (ja) * 2009-09-11 2011-03-17 宇部興産株式会社 N-置換ヘテロアリール化合物
CA2773998A1 (en) * 2009-09-11 2011-03-17 Ube Industries, Ltd. Substituted carbonyl compound
WO2011030873A1 (ja) * 2009-09-11 2011-03-17 宇部興産株式会社 ベンジル化合物
WO2011030865A1 (ja) * 2009-09-11 2011-03-17 宇部興産株式会社 置換ベンジル化合物
WO2011030872A1 (ja) * 2009-09-11 2011-03-17 宇部興産株式会社 スルホンアミド化合物
KR20120101722A (ko) * 2009-12-25 2012-09-14 우베 고산 가부시키가이샤 아미노피리딘 화합물
JP5964965B2 (ja) 2011-08-18 2016-08-03 ドクター レディズ ラボラトリーズ リミテッド コレステリルエステル転送タンパク質(cetp)インヒビターとしての置換複素環式アミン化合物
IN2014CN02290A (pt) 2011-09-27 2015-06-19 Reddys Lab Ltd Dr
CN104066837B (zh) 2011-12-02 2020-12-08 菲特治疗公司 增强的干细胞组合物
EP2785350B1 (en) 2011-12-02 2018-05-02 Fate Therapeutics, Inc. Improved methods of treating ischemia
EP2804605A4 (en) * 2012-01-20 2015-07-08 Acucela Inc SUBSTITUTED HETEROCYCLIC COMPOUNDS FOR THE TREATMENT OF DISEASES
CA2891595A1 (en) * 2012-11-16 2014-05-22 Allergan, Inc. Compounds and methods for skin repair
US10851412B2 (en) 2013-03-15 2020-12-01 Fate Therapeutics, Inc. Cell potency assay for therapeutic potential
BR112015024743A2 (pt) 2013-03-28 2017-07-18 Ube Industries composto de biarila substituída
HRP20241236T1 (hr) 2014-05-13 2024-12-06 Novartis Ag Spojevi i pripravci za induciranje hondrogeneze
CN106397149B (zh) * 2016-08-26 2019-05-21 大连奇凯医药科技有限公司 五氟苯甲醛的制备方法
CN115636761B (zh) * 2021-07-20 2024-07-05 中国石油天然气股份有限公司 一种油溶性表面活性剂、驱油剂及其应用

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2113787A1 (en) * 1993-01-29 1994-07-30 Nobuyuki Hamanaka Carbocyclic sulfonamides
DK0951282T3 (da) * 1996-12-20 2008-07-14 Pfizer Forebyggelse og behandling af skeletlidelse med EP2-receptorsubtype-selektive prostaglandin E2-agonister
UA67754C2 (uk) * 1997-10-10 2004-07-15 Пфайзер, Інк. Агоністи простагландину, фармацевтична композиція на їх основі (варіанти), спосіб нарощення та збереження кісткової маси у хребетних та спосіб лікування (варіанти)
US6376533B1 (en) * 2000-10-20 2002-04-23 Allergan Sales, Inc. Omega-cycloalkyl 17-heteroaryl prostaglandin E2 analogs as EP2-receptor agonists

Also Published As

Publication number Publication date
WO2004078169A8 (en) 2005-04-21
WO2004078169A1 (en) 2004-09-16
EP1601351A1 (en) 2005-12-07
TW200424176A (en) 2004-11-16
CA2518193A1 (en) 2004-09-16
CN1859903A (zh) 2006-11-08
BRPI0408061A (pt) 2006-02-14
ZA200506532B (en) 2007-03-28
NZ541828A (en) 2008-06-30
AU2004216898A1 (en) 2004-09-16
JP2006519250A (ja) 2006-08-24
KR20050105511A (ko) 2005-11-04
CL2004000412A1 (es) 2005-02-04
MXPA05009398A (es) 2005-12-05

Similar Documents

Publication Publication Date Title
IL164778A0 (en) Therapeutic use of selective pde10 inhibitors
GB0403969D0 (en) Tissue treatment device
PL2625953T3 (pl) Udojowe urządzenie i sposób jego użycia
EP1793879A4 (en) MEDICAL APPARATUS FOR APPLICATION TO THE SKIN
IL172418A0 (en) Therapeutic agents useful for treating pain
IL173386A0 (en) Use of adcc-optimized antibodies for treating weak patients
ZA200701193B (en) The use of N-aryl diazaspiracyclic compounds in the treatment of addiction
PL1638628T3 (pl) Urządzenie do obróbki krwi
GB0324761D0 (en) Use of compounds in therapy
IL204561A (en) A device for treating body tissues with a drug substance
EP1515725A4 (en) USE OF CYCLOTHIOCARBAMATE DERIVATIVES IN THE TREATMENT OF HORMONE-RELATED ILLNESSES
PL378026A1 (pl) Leczenie chorób z zastosowaniem pełnych agonistów receptora Ó-7 nACh
ZA200410409B (en) Use of thio-oxindole derivatives in treatment of hormonerelated conditions
GB0204525D0 (en) Medical therapy apparatus
PL1838301T3 (pl) Użycie resiniferatotoksyny (RTX) dla wytwarzania środka leczącego stany bólowe
IL175605A0 (en) Controlled release of topirimate in liquid dosage forms
IL178827A0 (en) Use of reboxetine for the treatment of pain
PL397023A1 (pl) Środek leczniczy do leczenia AIDS
EP1757241A4 (en) SURGICAL TREATMENT DEVICE
GB0415181D0 (en) Compounds for use in the treatment of infection
IL281624B1 (en) Ultrasound system for medical treatment
PL1799283T3 (pl) Urządzenie do obróbki krwi zawierające środek typu pręta do utrzymywania przedmiotów
GB2386839B (en) Apparatus for use in the treatment of choanal atresia
GB2419532B (en) Skin treatment device
GB0310147D0 (en) A composition for use in the treatment of a skin condition in a subject

Legal Events

Date Code Title Description
REFS Decisions on refusal to grant patents (taken after the publication of the particulars of the applications)